ReviewEndocrine, metabolic & immune disorders drug targets2025
Navigating Cardiovascular Challenges of Obesity: Exploring Preventive Approaches.
Review in Endocrine, metabolic & immune disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retrospective analysis of dietary risk factors and cardiovascular outcomes in angiocardiopathy.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of obesity has surged to epidemic proportions, posing a significant threat to public health in the twenty-first century. Beyond its established association with metabolic diseases, obesity profoundly impacts cardiovascular health, serving as a major risk factor for various cardiovascular illnesses (CVDs), including coronary artery disease, heart failure, hypertension, and stroke. Mechanistically, obesity triggers a cascade of pathophysiological processes, including chronic inflammation and insulin resistance, exacerbating atherosclerosis and endothelial dysfunction. Moreover, obesity correlates with metabolic abnormalities that further elevate the risk of cardiovascular events. As global community has faced the COVID-19 pandemic, and thus, the aftereffects of the pandemic might pose a spectrum of post-viral complications, including cardiovascular sequelae such as myocarditis and arrhythmias. Considering the intersectionality of obesity, COVID-19, and cardiovascular health are imperative, particularly as obese individuals face heightened risks of severe post-COVID-19 effects and subsequent cardiovascular complications. Lifestyle management emerges as a cornerstone in preventing and managing obesity-related cardiovascular risks, encompassing dietary modifications, physical activity, behavioural therapies, and patient education. Embracing innovative approaches, including modulation of gut microbiota and novel drug developments, holds promise in addressing the intricate nexus between obesity and cardiovascular diseases. This review underscores the paramount importance of lifestyle interventions over pharmacological measures, advocating for a comprehensive approach involving healthcare practitioners, researchers, and policymakers to mitigate the long-term cardiovascular consequences of obesity and COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.